
REGENXBIO Inc.
NASDAQ•RGNX
CEO: Mr. Curran M. Simpson M.S.
セクター: Healthcare
業種: Biotechnology
上場日: 2015-09-17
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
連絡先情報
時価総額
$407.01M
PER (TTM)
-2.3
19.5
配当利回り
--
52週高値
$16.19
52週安値
$5.04
52週レンジ
順位61Top 91.5%
2.0
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q3 2025 データ
売上高
$29.73M+22.88%
直近4四半期の推移
EPS
-$1.20+2.56%
直近4四半期の推移
フリーCF
-$56.45M+38.11%
直近4四半期の推移
2025 Q3 決算ハイライト
主なハイライト
Nine Month Revenue Surge Total revenues reached $140.104M for nine months, up $77.976M, driven by Nippon Shinyaku upfront fee recognition.
Royalty Revenue Nearly Doubles License/royalty revenue hit $129.119M for nine months, up $67.947M, primarily from Zolgensma royalties.
Net Loss Significantly Narrows Nine-month net loss improved to $(126.729M), representing a favorable change of $49.187M versus prior period.
Cash Position Strengthened Cash, equivalents, and securities totaled $302.0M, bolstered by recent financing and collaboration proceeds.
リスク要因
High Cumulative Losses Accumulated deficit reached $1.06B; profitability depends heavily on successful product approval and commercialization.
Rising R&D Investment R&D expenses rose $10.546M to $168.688M for nine months, driven by manufacturing and clinical supply costs.
GSK Sublicense Fee Dispute Company disputes GSK claim regarding sublicense fees; no loss estimated, but legal uncertainty remains for operations.
Future Capital Requirements Expect significant additional capital needed to fund operations for several years before achieving recurring profitability.
見通し
RGX-314 Pivotal Data Expected ABBV-RGX-314 pivotal trial enrollment complete; expect sharing of topline data globally in fourth quarter 2026.
RGX-202 BLA Submission RGX-202 BLA submission anticipated mid-2026 via accelerated pathway following imminent Process Performance Qualification completion.
RGX-121 Approval Timeline RGX-121 BLA review timeline extended to February 8, 2026, following FDA request for 12-month clinical data.
New Financing Strategy Plan to secure significant additional capital through equity offerings, debt financings, or strategic alliances for operations.
同業比較
売上高 (TTM)
RGNX$161.32M
GOSS$44.05M
BCYC$28.34M
粗利益率 (最新四半期)
BCYC100.0%
GOSS100.0%
ABSI100.0%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| OLMA | $1.78B | -12.9 | -41.5% | 1.3% |
| CRVS | $1.47B | -96.1 | -25.8% | 1.3% |
| MLTX | $1.24B | -5.3 | -56.2% | 18.3% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
11.9%
安定成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
25%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年3月12日
EPS:-$0.99
|売上高:-
財務レポート
財務データ
ニュース
全年度
Form 10-Q - Q3 2025
会計期末: 2025年9月30日|提出日: 2025年11月6日|売上高: $29.73M+22.9%|EPS: $-1.20+2.6%予想を上回るForm 10-Q - Q2 2025
会計期末: 2025年6月30日|提出日: 2025年8月7日|売上高: $21.36M-4.2%|EPS: $-1.38+31.4%予想を下回るForm 10-Q - Q1 2025
会計期末: 2025年3月31日|提出日: 2025年5月12日|売上高: $89.01M+469.8%|EPS: $0.12-108.7%予想を下回るForm 10-K - FY 2024
会計期末: 2024年12月31日|提出日: 2025年3月13日|売上高: $83.33M-7.7%|EPS: $-4.59+23.8%予想を下回るForm 10-Q - Q3 2024
会計期末: 2024年9月30日|提出日: 2024年11月6日|売上高: $24.20M-16.3%|EPS: $-1.17-17.0%予想を下回るForm 10-Q - Q2 2024
会計期末: 2024年6月30日|提出日: 2024年8月1日|売上高: $22.30M+11.6%|EPS: $-1.05-36.7%予想を上回るForm 10-Q - Q1 2024
会計期末: 2024年3月31日|提出日: 2024年5月8日|売上高: $15.62M-18.4%|EPS: $-1.38-14.3%予想を下回るForm 10-K - FY 2023
会計期末: 2023年12月31日|提出日: 2024年2月27日|売上高: $90.24M-19.9%|EPS: $-6.02+7.4%予想を下回る